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Lung cancer is the most common cancer in the world. Despite modern advancements in
surgeries, chemotherapies, and radiotherapies over the past few years, lung cancer still
remains a very difficult disease to treat.This has left the death rate from lung cancer victims
largely unchanged throughout the past few decades. A key cause for the high mortality
rate is the drug resistance that builds up for patients being currently treated with the
chemotherapeutic agents. Although certain chemotherapeutic agents may initially effec-
tively treat lung cancer patients, there is a high probability that there will be a reoccurrence
of the cancer after the patient develops resistance to the drug. Erlotinib, the epidermal
growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor, has been approved for
localized as well as metastatic non-small cell lung cancer where it seems to be more effec-
tive in patients with EGFR mutations. Resistance to erlotinib is a common observation in
clinics and this review details our current knowledge on the subject.We discuss the causes
of such resistance as well as innovative research to overcome it. Evidently, new chemother-
apy strategies are desperately needed in order to better treat lung cancer patients. Current
research is investigating alternative treatment plans to enhance the chemotherapy that is
already offered. Better insight into the molecular mechanisms behind combination therapy
pathways and even single molecular pathways may help improve the efficacy of the current
treatment options.
Keywords: erlotinib, lung cancer, tyrosine kinase inhibitors, drug resistance, non-small cell lung cancer
INTRODUCTION
Lung cancer is a leading cause of cancer-related deaths and has one
of the lowest survival rates among all cancers. In 2008, lung cancer
was found to be the most commonly diagnosed cancer as well as
the primary cause of cancer-related mortality for males worldwide
and the second leading cause of cancer-related deaths for women
(Jemal et al., 2011; Nurwidya et al., 2012). For the year 2012, it
is estimated that lung cancer will account for 26% of all female
cancer deaths and 29% of all male cancer deaths (Siegel et al.,
2012). These statistics are consistent with tobacco usage in both
genders. Furthermore, lung cancer is associated with poor prog-
nosis because in many cases, the tumor is asymptomatic for a long
duration of time (Saintigny and Burger, 2012). Many patients are
diagnosed at a more advanced stage when surgery is no longer an
option. Currently, metastasis and drug resistance are major prob-
lems that make treatment so difficult and add to the recurrence
of the cancer. When non-small cell lung cancer (NSCLC) patients
are treated with the most active forms of chemotherapeutic agents,
their median survival period is only about 8–10 months (Ohe et al.,
2007).
Drug resistance typically affects patients in one of two methods.
Some patients may already have intrinsic resistance to the types of
drugs offered through chemotherapy. In other cases, patients may
initially be effectively treated with chemotherapy, but eventually
develop more resistance over time, despite the utilization of a com-
bination of therapeutic agents (Xiao and He, 2010). Currently,
there are numerous attempts to overcome drug resistance to bet-
ter the efficacy of chemotherapy. In addition to surgeries, patients
may face several different treatment paths, including radiother-
apy (RT) and chemotherapy. There are also different methods in
treating lung cancer patients with chemotherapy, including mole-
cular targeted therapy. Although recent research has found several
combination therapies that have successfully enhanced treatment
of individual lung cancer cell lines, research has yet to discover
an effective treatment plan that successfully heals all lung can-
cer patients. Further studies on the molecular mechanisms of
combination chemotherapeutic agents may help improve current
therapy treatment plans.
SMALL CELL LUNG CANCER
Lung cancer can be broadly divided into two categories for prog-
nostic and treatment purposes: small cell lung cancer (SCLC) and
NSCLC. SCLC is a type of lung cancer that is characterized by short
cell doubling time, rapid, aggressive progression, and early occur-
rence of blood-borne and lymph metastasis (Chen et al., 2012).
It originates from neuroendocrine bronchial cells and currently
accounts for approximately 15–20% of all lung cancer patients
(Rodriguez and Lilenbaum, 2010). Patients with SCLC express the
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highest malignancy of all lung cancer types. Currently, those with
SCLC initially respond well to chemotherapy and RT, but relapse
is a common problem after the initial treatment. Typically, only
about 2% of SCLC patients face a 5-year survival. Furthermore,
drug resistance, and particularly multi-drug resistance (MDR), has
become one of the main reasons for failure in SCLC patients (Chen
et al., 2012). Research shows that both single factors and multiple
factors combined may lead to MDR and counteract the positive,
initial effects of chemotherapy.
The molecular mechanism behind MDR in SCLC involves
various factors. Past research has shown that known drug resis-
tance mechanisms include the overexpression of outer mem-
brane proteins and lung resistance-related proteins, abnormal-
ity of the intracellular enzyme system, enhancement of the cell
repair system, and dysregulation of cell apoptosis (Chen et al.,
2012). Furthermore, mutation of key genes in the body may
also catalyze the development of drug resistance (Roberti et al.,
2006). The gene expression profiles, which consist of activation
of proto-oncogenes and inactivation or loss of tumor suppres-
sor genes, are comparatively specific for SCLC patients (Fong
et al., 1999). SCLC has been divided into either classic or vari-
ant types. Classic types generally express high differentiation
and sensitivity to chemotherapy while variant types express low
differentiation, have a fast growth rate and respond poorly to
chemotherapy.
NON-SMALL CELL LUNG CANCER
Non-small cell lung cancer is the most common type of lung
cancer and accounts for approximately 80–85% of all patients
who have been diagnosed with lung cancer (Herbst et al., 2008;
Chunhacha and Chanvorachote, 2012). These lung cancer cells
can again be categorized based on their histological characteris-
tics as squamous cell carcinoma, large cell carcinoma, and ade-
nocarcinoma (Pore et al., 2010). NSCLC spreads slower than
SCLC, so many patients who are diagnosed at an earlier stage
are potentially curable, though NSCLC may often relapse at
other metastatic sites. Furthermore, NSCLC is generally less
responsive to chemotherapy than SCLC, so that even with sur-
gical resection at early diagnosis, approximately 50% of NSCLC
patients face recurring cancers (Kelsey et al., 2006). Moreover,
approximately 40–75% of stage I to stage IIIA NSCLC patients
are projected to die within 5 years even with surgery (Shapiro,
2012).
Numerous chemotherapeutic agents are already being uti-
lized to treat NSCLC patients. For example, the drug Cis-
diamminedichloroplatinum (II; cisplatin), a platinum-based ther-
apeutic treatment, is usually utilized to treat NSCLC and has been
shown to effectively improve patient survival (Olaussen et al.,
2006). However, there are also negative effects of using cisplatin,
such as toxic side-effects, which include nausea, emesis, renal fail-
ure, ototoxicity, and neurotoxicity (Barabas et al., 2008; Tsang et al.,
2009). Due to the toxic side-effects and failure to treat patients
long-term, cisplatin is not an ideal chemotherapeutic for NSCLC
patients. Recent research has explored the development and pro-
duction of different anti-cancer agents that may target specific
molecular pathways, which may result in lower toxicity levels and
decreased possibilities of negative side-effects.
CURRENT CLINICAL MANAGEMENT OF LUNG CANCER
Although there is currently no long-term chemotherapeutic agent
that effectively treats lung cancer patients, clinics offer a wide range
of treatment options that still may help prolong patient life. Treat-
ment options differ based on the histologic form of cancer, the
cancer stage, and the patient’s functional ability (Collins et al.,
2007). The majority of stage I through stage IIIA lung cancer
patients generally choose surgery as their primary option (Beckles
et al., 2003). Another popular option is preoperative chemother-
apy, which has been shown to improve survival rate in patients
with NSCLC. Patients who require complete resection and no
preoperative chemotherapy usually invest in adjuvant chemother-
apy (Skinner et al., 1991). For patients with unresectable NSCLC,
RT, and chemotherapy are excellent options for treatment. Fur-
ther, certain agents have been combined with the chemotherapy
to enhance its effects. The antivascular endothelial growth factor
agent bevacizumab, for example, when combined with chemother-
apy, has resulted in increased survival rate when compared to
chemotherapy treatment alone (Sandler et al., 2006).
Furthermore, treatments are also recommended based on their
probability of efficacy. For first-line chemotherapy, a platinum-
based two-drug combination is suggested for patients (Azzoli et al.,
2009). Studies show that the drug cisplatin, when used in combi-
nation chemotherapy, is associated with improved response rates,
no change in survival rate, and increased toxicity when com-
pared with the drug carboplatin (Ardizzoni et al., 2007). Also,
the aforementioned drug bevacizumab has demonstrated great
potential when used in combination with carboplatin or paclitaxel
in NSCLC patients. Another drug, cetuximab, which is an EGFR
monoclonal antibody, has also enhanced survival when used in
combination with cisplatin and vinorelbine in patients positive
for EGFR expression. There are various drugs that are considered
relatively effective as a first-line therapeutic, depending on the lung
cancer.
The second-line chemotherapy treatment options, which are
suggested after primary treatment fails to yield effective results,
do differ from the first-line drugs. Approximately 30% of NSCLC
patients who undergo first-line cancer treatment are candidates
for second- or third-line therapy. The first agent that was approved
for second-line therapeutics was docetaxel (Fossella et al., 2000).
Other drugs that were also soon approved include pemetrexed,
erlotinib, and gefitinib (Hanna et al., 2004; Kim et al., 2008).
However, recent studies have explored an alternative non-cross
resistance therapy, known as switch maintenance or continu-
ation maintenance therapy, which can be used after first-line
therapy in place of the cytotoxic chemotherapy that the afore-
mentioned drugs fulfill (Azzoli et al., 2011). Switch maintenance
aims to immediately treat patients with an alternative, single-agent
chemotherapy. For example, pemetrexed would be suggested for
patients with non-squamous histology and docetaxel, erlotinib,
or gefitinib for unselected patients (Ciuleanu et al., 2009; Fidias
et al., 2009; Cappuzzo et al., 2010; Takeda et al., 2010). Research
is currently still exploring other possible second-line therapeutic
options and improving current treatment plans.
Cancer pain, which can arise from local effects of the cancer,
regional spread of the tumor, or from anti-cancer therapy, is one
of the most common symptoms of lung cancer and also needs
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to be treated. Lung cancer patients experience more symptom
distress than any other cancer patients (Caraceni and Portenoy,
1999; Cooley, 2000; Simmons et al., 2012). The pain is charac-
terized into acute pain or chronic pain, which usually differ by
duration of pain and predictability (Carr and Goudas, 1999). The
World Health Organization (WHO) has created a series of steps to
treat cancer patients for pain relief, including treatment with the
anti-inflammatory drug paracetamol, weak opioids (e.g., codeine),
morphine, or adjuvant analgesics (Hanks et al., 2001). If these steps
fail to alleviate the pain, other interventional procedures which aim
to interrupt or modify nerve conduction are also available.
EPIDERMAL GROWTH FACTOR RECEPTOR
The epidermal growth factor receptor (EGFR) is a tyrosine kinase
that contributes to the regulation of cellular homeostasis (Cohen,
1965; Nicholson et al., 2001; Wheeler et al., 2010). It is a 170 kDa
membrane protein that stimulates downstream cell signaling cas-
cades that could influence migration, apoptosis, cell prolifera-
tion, survival, and tumorigenesis (Hynes and Lane, 2005). The
EGFR family consists of four members, including HER1/ErbB1,
HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4 (Giaccone and
Wang, 2011). EGFR has been implicated in the growth of several
human epithelial malignancies, including lung cancer. It is over-
expressed in several cancers, including approximately 40–80% of
NSCLC, which made EGFR a popular target for new drug treat-
ment exploration (Salomon et al., 1995; Rusch et al., 1997; Braben-
der et al., 2001). Thus, targeting EGFR has been a fairly recent
topic of research for cancer therapeutics, with a resultant series
of potential molecular inhibitors that may be pursued in clinical
oncology. The difficulties with EGFR inhibitor therapy also deals
with drug resistance and longevity of chemotherapy. The connec-
tion between EGFR alteration and tumorigenesis makes it an ideal
contender for molecularly targeted therapy (Wu et al., 2012). A
better understanding of the molecular mechanisms behind EGFR
inhibitors and drug treatment resistance would greatly improve
the current chemotherapies offered.
EGFR MUTATIONS
Studies have identified some EGFR mutations in the tyrosine
kinase domain in NSCLC patients which may help predict ther-
apeutic results with tyrosine kinase inhibitors (TKIs), erlotinib,
and gefitinib (Paez et al., 2004; Pao et al., 2004). These mutations,
including in-frame deletion of several amino acids, resulted in
tumors that became significantly more responsive to treatment by
erlotinib and gefitinib than tumors that did not have EGFR muta-
tions. These studies have advanced our understanding of the role
of EGFR mutations in interacting with TKIs, but currently there
is not enough research to form a reliable antibody-based EGFR
therapy (Mukohara et al., 2005).
Approximately half of the NSCLC tumors found in patients
who initially responded to first-generation EGFR TKIs and then
develop resistance have another mutation, known as the T790M
point mutation in EGFR (Sharma et al., 2007; Suda et al.,
2009). The T790M mutation could also initially combine with
erlotinib or gefitinib in the body and also contribute to initial
drug resistance. Furthermore, when treated with first-generation
TKIs, the T790M cells are expressed with an increasingly larger
percentage of the tumor mass over time (Inukai et al., 2006).
The mutation may also aid in faster tumor growth, especially
when occurring in concurrence with another EGFR-activating
mutation. In addition, other EGFR mutations have also demon-
strated contribution to the development of drug resistance to
erlotinib and gefitinib, including secondary EGFR kinase muta-
tions, L858R mutations, and secondary D761Y point mutations.
Better understanding of the molecular mechanisms behind EGFR
mutations may benefit the use of TKIs for chemotherapy in the
future.
ERLOTINIB
The introduction of EGFR inhibitors, such as erlotinib, has been
an important advancement in targeted chemotherapy. Erlotinib
is an EGFR-specific TKI that has been approved by the Food and
Drug Administration to be used as a molecularly targeted drug for
lung cancer patients (Sierra et al., 2010; Diep et al., 2011; Kosaka
et al., 2011). Erlotinib functions by reversibly inhibiting EGFR
through competitive binding at the ATP site in the tyrosine kinase
domain, which results in fewer downstream proliferative signal-
ing pathways (Steins et al., 2010; Nguyen and Neal, 2012). It has
been shown to be effective in patients whose tumors express EGFR
mutations (Shepherd et al., 2005). The overexpression of EGFR in
tumors has been linked to poor prognosis due to its association
with tumor progression, angiogenesis, migration, and metastasis
(Yarden, 2001; Mehta, 2012). Erlotinib is highly utilized in can-
cer therapy due to its relatively few side-effects and high efficacy
in patient responders of this TKI (Lee and Wu, 2012). Initially,
erlotinib was approved in 2004 as monotherapy for patients with
NSCLC, and then in 2005, it was approved as for combination
chemotherapy with gemcitabine (Wheeler et al., 2010). However,
erlotinib has been shown to be ineffective for the majority of lung
cancer patients because the patients are either initially resistant
to the inhibitor or eventually develop resistance. Statistics show
that approximately 10–14 months after the primary treatment of
erlotinib, NSCLC patients start to develop resistance to the agent,
which results in reoccurring lung cancer (Kosaka et al., 2011;
Oxnard et al., 2011). In order to better treat patients with NSCLC,
further studies should explore the molecular mechanisms behind
erlotinib resistance development.
ERLOTINIB RESISTANCE
Epidermal growth factor receptor TKIs, such as erlotinib, are
commonly utilized as part of cancer therapy. However, drug resis-
tance is a great problem in sustaining the efficacy of such drugs.
Recent studies have revealed that there is a strong link between
the mesenchymal-to-epithelial transition factor (MET) activation
and amplification and resistance to TKIs (Gusenbauer et al., 2012).
MET, which is a proto-oncogene that encodes the receptor for
the hepatocyte growth factor (HGF), is associated with induc-
ing cell invasion and metastasis (Birchmeier et al., 2003). MET
is also usually expressed along with EGFR in several human can-
cers, including lung cancer (Weinberger et al., 2005). HGF has been
shown to activate Met and stimulate short-term resistance to EGFR
TKIs. After examining the function of HGF by treating cancer
tissues with it, which resulted in completely blocked EGFR tyro-
sine kinase activity (Weinberger et al., 2005). Thus, HGF-induced
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inhibition of EGFR TKIs is shown to be a common occurrence in
human cancers.
The acquisition of epithelial-to-mesenchymal transition
(EMT) is associated with increased cell invasion, migration, and
proliferation and loss of cell adhesion proteins in numerous can-
cer cell lines and linked to the progression of cancer malignancies
(Maitah et al., 2011). EMT is observed in many epithelial can-
cers, including NSCLC. Research suggests that EMT markers may
be linked to EGFR inhibitors. A recent study that examined both
epithelial and mesenchymal cell sensitivity to erlotinib found that
mesenchymal cells exhibited increased resistance to the EGFR
inhibitor in comparison to epithelial cells (Byers et al., 2013).
Furthermore, this study was able to predict erlotinib sensitivity
in EGFR-mutant and EGFR-wild type NSCLC based on EMT
score. EGFR-wild type patients who showed progress from treat-
ment with EGFR TKIs were effectively identified in several clinical
studies. More importantly, it was revealed that the Axl inhibitor
SGI-7079, which is expressed highly in mesenchymal cells, could
reverse erlotinib resistance in mesenchymal cell lines when used in
combination with erlotinib (Byers et al., 2013). This breakthrough
may help improve the longevity of cancer treatment with erlotinib.
Researchers have been exploring more innovative methods to
battle erlotinib drug resistance. For example, recent studies have
shown that the manner in which patients are treated with erlotinib
affects the efficacy and longevity of the therapy. It was revealed
that high-dose pulses with low-dose continuous treatment with
erlotinib impeded the development of resistance in both cases of
pre- and post-emergence of resistance (Foo et al., 2012). Drug
resistance has a higher probability of developing in fast drug
metabolizers, which indicates that there is a potential mechanism
that influences the development of drug resistance in patients. The
results of this study should be further explored to enhance current
kinase inhibitor knowledge and improve dosing strategies.
Another associated cause of drug resistance may be due to the
methylation of death-associated protein kinase (DAPK). Emerging
studies have linked epigenetic changes, including DNA methyla-
tion at CpG islands, to the development of drug resistance to many
anti-cancer drugs (Ogawa et al., 2012). Evidence also indicates that
genes that are differentially methylate are potential biomarker can-
didates. A recent study found that the DAPK is hypermethylated
in drug-resistance derivatives. Moreover, restoration of DAPK in
drug resistance NSCLC cells resulted in the re-sensitization of cells
to therapeutic agents, including erlotinib and cetuximab (Ogawa
et al., 2012). The results suggest that DAPK may play an important
function in erlotinib resistance. It would be beneficial to further
explore gene silencing through promoter methylation.
COMBINATION THERAPY TO IMPROVE TREATMENT WITH
ERLOTINIB
A recent study investigated the efficacy of a low-dose combina-
tion treatment of erlotinib and cisplatin in lung adenocarcinoma
to better comprehend the role of autophagy in erlotinib resis-
tance (Lee and Wu, 2012). Exploring the relationship between
drug resistance and cell autophagy is important because autophagy
functions in cell protein homeostasis and degradation of injured
cellular organelles (Hsieh et al., 2009). Thus, impaired autophagy
is associated with several human diseases, such as cancer, but the
exact role it plays in cancer resistance remains uncertain (Shimizu
et al., 2012). The result demonstrated that a low-dose erlotinib-
cisplatin combination was able to overcome erlotinib resistance
and also stimulate synergistic cell death. The treatment also exhib-
ited low toxicity to the sample cells. Furthermore, the study found
that altering the level of autophagy affected the cell’s sensitiv-
ity to erlotinib. Although researchers had success in overcoming
drug resistance in a single cell line, this does not suggest that the
treatment will be effective for all NSCLC patients. In many cases,
combinations of chemotherapy and anti-cancer agents have been
used for chemotherapy. However, the treatments are not effective
for all other differing cell lines. The current research is an effective
start to exploring the molecular mechanisms behind drug resis-
tance and cell autophagy. Further exploration of this idea may
yield more insight into a generalized drug combination that may
effectively treat all lung cancer patients.
Another study demonstrated how other combination therapies
may improve the current erlotinib treatment. The study found
that the ATP non-competitive CDK-2/cyclin A inhibitor NBI1
will help sensitize tumor cells that have developed resistance to
erlotinib to combination therapy for cell apoptosis (Orzaez et al.,
2012). In addition, for tumor cells that were sensitive to erlotinib,
the effective dose of erlotinib was lower when the inhibitor NBI1
was present. Combining TAT-NBI1 with erlotininb reduces the
lethal dose of erlotinib in the erlotinib-sensitive cells and it also
tumor cells that are resistant to erlotinib to apoptosis. This study
emphasized the value in researching the therapeutic effects of
EGFR inhibitors when utilized in conjunction with ATP non-
competitive CDK-2/cyclin A inhibitors. This study focused on the
NBI1 inhibitor, but further exploration of other CDK-2/cyclin A
inhibitors may also prove valuable to the chemotherapeutic effects
of erlotinib treatment.
In addition to the combination therapy of CDK-2/cyclin A
inhibitors, another study examined the effect of the histone
deacetylase (HDAC) inhibitor trichostatin A (TSA) to enhance
the effects of erlotinib (Zhang et al., 2012). HDAC inhibitors
are anti-cancer agents with the potential to enhance treatment of
human cancers and TSA is a specific inhibitor of HDAC that can
result in cell growth arrest. This study investigated the combining
effect of TSA with erlotinib in A549 lung cancer cells. Results
demonstrated that molecular targeted chemotherapy with this
combination of agents led to a considerable increase in cleaved
caspase-3 expression, which resulted in decreased expression of
EGFR. This research provides in vitro support that TSA can inhibit
cancer growth by contributing to the stimulation of cell apopto-
sis. Further research on the mechanism behind this pathway is
encouraged for better understanding of this combination therapy
and its effects on lung cancer.
A study that observed the effect of erlotinib combined with
pemetrexed also yielded encouraging results. Both erlotinib and
pemetrexed are currently approved for second-line treatment for
advanced NSCLC patients. Pemetrexed is a multi-targeting antifo-
late cytotoxic agent that generally inhibits several enzymes associ-
ated with the folate metabolism, including thymidylate synthase,
dihydrofolate reductase, and glycinamide ribonucleotide formyl
transferase (Hanauske et al., 2001). When cancer cells are treated
with pemetrexed, they are arrested in cell growth and then undergo
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cell apoptosis. The phase I study explored the treatment of lung
cancer cells with a combination of erlotinib and permetrexed,
which was well-tolerated and fairly successful in antitumor efficacy
(Minami et al., 2012). More research on the effect of combination
therapy with these two agents is undergoing phase II study.
More research on combinational therapy explored the possibil-
ity of therapy with erlotinib combined with enzastaurin. Enzastau-
rin, which is an oral serine/threonine kinase inhibitor that targets
the protein kinase C (PKC) and phosphatidylinositol-3-kinase
(PI3K) pathways, affects signal transduction linked to angiogene-
sis, apoptosis, and cell proliferation (Partovian and Simons, 2004).
A current study that explored the treatment of patients with
advanced stage IIIB or IV NSCLC with erlotinib and enzastaurin.
Results revealed that while the enzastaurin did not help improve
the patient response to chemotherapy, it did not worsen usual
results either (Clement-Duchene et al., 2012). Overall, the com-
bination therapy presented to be well tolerated in the NSCLC
patients. This is a common outcome in combination therapy
tests. Although several combinations of therapeutic agents may
not improve patient outcome, in many cases, the combination
therapy is simply well tolerated and does not improve or worsen
patients who are treated singularly with erlotinib. Another exam-
ple of this situation is observed in a study of combination therapy
with erlotinib and tivantinib. Tivantinib is a selective oral, non-
ATP-competitive inhibitor of the MET receptor tyrosine kinase
(Goldman et al., 2012). Since the MET gene is associated with
inducing tumor resistance to EGFR inhibition, tivantinib seems
to have a promising role in overcoming drug resistance. How-
ever, the result of treating NSCLC patients with tivantinib and
erlotinib resulted in well tolerated clinical activity. Patients did
not experience significantly worse or better outcomes.
Another potential combination of therapeutic agents is treat-
ing NSCLC patients with erlotinib and cetuximab. Cetuximab is a
monoclonal antibody that directs against the extracellular domain
of EGFR. It functions in inhibiting phosphorylation and stim-
ulates internalization. A recent study demonstrated that using a
combination of erlotinib and cetuximab reversed the drug resis-
tance in NSCLC in T790M and L858R mutation lung cancer cell
lines (Wang et al., 2012). When compared to single treatment with
erlotinib, the combination of agents led to increased apoptosis
of EGFR TKI-resistance cells, decreased cell proliferation, and
increased inhibition of EGFR-dependent signaling. This combi-
nation of drugs shows great potential in helping to mediate the
growing drug resistance problem.
In addition to its combination treatment for chemotherapy,
erlotinib has also been considered as an option in combination
with RT. A recent study explored the effects of erlotinib combined
with RT in numerous cancer types, including lung cancer. Since
erlotinib contributes to the disruption of cell growth pathways
and stimulates cell sensitivity to the effects of RT, it was predicted
that combination therapy would be effective in treating lung can-
cer (Chinnaiyan et al., 2005; Baumann et al., 2007). It was also
predicted that RT would help enhance the efficacy of erlotinib by
cytoreducing tumors and creating a hypoxic environment (Tor-
tora et al., 2007). The study reported that combining erlotinib and
RT yielded moderate improvements and toxicities have been man-
ageable (Mehta, 2012). Trials with this combination of therapy is
now undergoing phase III trials, which should hopefully yield new
insight into pairing erlotinib with other forms of cancer therapy.
OVERCOMING DRUG RESISTANCE
RESISTANCE TO EGFR INHIBITORS
Recent research is investigating a more resistive form of inhibitors
to use for chemotherapy. Many studies are focusing on irreversible
inhibitors that will concurrently target multiple members of the
EGFR family (Giaccone and Wang, 2011). The first-generation
erlotinib binds to the catalytic site of the EGFR tyrosine kinase
domain through competitive binding with ATP (Suda et al., 2009).
Thus, the irreversible binding mechanism of the next-generation
erlotinibs, and other TKIs, is expected to increase the effectiveness
of the inhibitors by prolonging the inhibition of EGFR signal-
ing and decreasing developments to resistance. It is predicted that
the irreversible inhibitor will covalently bind to the EGFR and no
longer function in a competitive, reversible bind with ATP (Yun
et al., 2008).
The realization that other EGFR family members, specially
HER2, compensate for EGFR-targeted therapies, led to the devel-
opment of irreversible inhibitors such as BIBW 2992/afatinib
(Doebele et al., 2010; Spicer and Rudman, 2010; Kwak, 2011),
HKI-272 (Doebele et al., 2010), and PF00299804 (Ercan et al.,
2010; Kwak, 2011). Clinically, it is observed that almost all the
NSCLC patients who initially show signs of disease stabilization
through EGFR TKI, finally progress to secondary resistance (Batus
et al., 2010). For such patients, irreversible EGFR TKIs hold a lot
of promise. The irreversible TKI BIBW 2992 (afatinib) is cur-
rently being investigated in advanced clinical trials (Yap et al.,
2010; Murakami et al., 2012). Another novel irreversible pan-HER
inhibitor HM781-36B has recently shown promise in the inhibi-
tion of EGFR, HER2, and HER4 as well as against the gatekeeper
mutation – EGFR T790M that is responsible for acquired drug
resistance in lung cancer patients (Cha et al., 2012).
DRUG RESISTANCE-REVERSING AGENTS
A developing strategy to counteract drug resistance progression
in SCLC is to target the mitochondrial apoptosis pathway. An
example is the anti-apoptotic gene Bcl-2 which is commonly over-
expressed in SCLC cells and tissues (Hann et al., 2008). This is also
associated with the apoptosis escape of tumor cells and chemore-
sistance (Rudin et al., 2004). In addition, another study found that
in a phase I clinical trial, the Bcl-2 targeted inhibitor Oblimersen
relieved approximately 86% of untreated SCLC patients (Olters-
dorf et al., 2005). The Bcl-2 targeted inhibitors are divided into
two groups: antisense oligonucleotides and small molecular weight
inhibitors.
NEW CHEMOTHERAPEUTIC AGENTS
Several new chemotherapeutic agents have been developed that
are predicted to increase the success of chemotherapy. Such drug
treatments include amrubicin, SABA, picoplatin, belotecan, and
vinflunine (Chen et al., 2012). Amrubicin, for example, is a syn-
thetic anthracycline that aids in blocking NDA repair by inhibiting
Topoisomerase I. Already, clinical trials have resulted in increased
response rates as high as 88% from combined utilization of amru-
bicin and picoplatin, which is a platinum analog that functions
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in overcoming platinum drug resistance (Tang et al., 2011). The
median survival period is also recorded to be 13.6 months among
SCLC patients. Furthermore, phase II clinical trials have also
demonstrated the beneficial therapeutic activity of amrubicin and
picoplatin in relapsed SCLC patients (Jeong et al., 2010). A new
experimental treatment has recently been explored. Picoplatin,
which is a new platinum compound created to surmount other
platinum agents, has already exhibited decreased neurotoxicity
and nephrotoxicity than other platinum compounds (Nair et al.,
2011). However, the study reported that the picoplatin did not
exhibit any improvements in overall survival rate when compared
to other chemotherapeutic agents (Eckardt et al., 2009). Further
exploration of new chemotherapeutic agents may prove to be very
beneficial to helping SCLC patients overcome drug resistance.
TARGETED THERAPIES
Better understanding of the molecular biology behind various
SCLC treatment pathways has yielded new, promising targets.
Recently, novel molecularly targeted drug treatments have been
developed, including matrix metalloproteinase (MMP) inhibitors,
thalidomide, biological vaccines, and small molecular weight
inhibitors directed at receptor protein tyrosine kinases. Many of
these have been tested in phase II clinical trials for success in over-
coming drug resistance (Chen et al., 2012). However, most of these
aforementioned treatments have failed thus far in demonstrating
efficacy in clinics (Dy and Adjei, 2002; Antonia et al., 2006; Khan-
zada et al., 2006; Lee et al., 2008; William and Glisson, 2011).
Another treatment in particular, of which efficacy is pending, is
the use of simvastatin or pravastatin. Earlier studies found that
simvastatin can inhibit SCLC growth, induct tumor cell apopto-
sis, and increase the sensitivity of SCLC to etoposide (Weiss et al.,
1999). Pravastatin yields similar inhibitory effects on SCLC, and
phase III clinical trials are still in effect.
MICRORNAs
MicroRNAs (miRNAs) are small regulatory RNA molecules that
post-transcriptionally regulate gene expression by targeting mes-
senger RNAs (mRNAs; Croce and Calin, 2005; Fabian and Sonen-
berg, 2012). miRNAs play important roles in many cellular
processes, including tumorigenesis. They are involved in many
pathways associated with lung cancer. For example, ErbB2, ErbB3,
and ErbB4 are all part of a family of tyrosine kinase receptors
whose overexpression results in tumorigenesis and cancer cell
proliferation (Holbro et al., 2003; Kiran and Deepika, 2012). Fur-
thermore, miRNAs are also associated with the regulation of EGFR
in lung cancer. The inhibition of miR-128, for example, led to
upregulation of EGFR expression in an EGFR-expressing NSCLC
cell line (Weiss et al., 2008). In addition, inhibition of miR-21
resulted in increased anti-apoptotic potential of an anti-EGFR
tyrosine kinase inhibitor in an EGFR-mutant lung adenocarci-
noma cell line (Seike et al., 2009). Another example can be seen in
miR-29, which is downregulated in several human cancers, includ-
ing lung cancer. miR-29 regulates epigenetic DNA methylation,
which suggests that enhancing expression of this miRNA may
effectively function as a therapeutic agent (Fabbri et al., 2007).
In addition to the aforementioned miRNAs, studies have demon-
strated the association between numerous other miRNAs and lung
cancer therapy. Further investigation of the molecular mecha-
nisms of other miRNAs may provide better insight into cancer
therapeutics and how to utilize miRNAs to enhance therapy.
CONCLUSIONS
Cancer research has progressed rapidly and led to the develop-
ment of several methods of treatment, including molecular tar-
geted chemotherapy. Although several chemotherapeutic agents
have proven to be quite effective in treating numerous patients
with lung cancer, in the majority of cases, patients either already
were resistant to the effects of the drug or eventually developed
resistance as time progressed. Erlotinib, for example, typically is
effective on patients with EGFR mutations, but generally does
not successfully treat lung cancer patients without malignancy
reoccurrence. Although numerous mechanisms for drug resis-
tance have been developed, they are not able to effectively account
for all cases of drug resistance. However, research has shown
promising potential in targeting multiple tumorigenic pathways
simultaneously. Combination therapy with erlotinib has already
demonstrated success in numerous lung cancer cell lines. Antitu-
mor effects have already been observed in several studies. Current
studies are exploring new agents to enhance chemotherapy and
focusing on identifying potential predictors of treatment bene-
fit (Leighl, 2012). Further investigation of these pathways may
improve our knowledge of the antitumor efficacy and longevity,
which will hopefully improve treatment options for lung cancer
patients.
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